Evidence map›Paper›PMID 27363700›Full record

ArticlePathology oncology research : POR2017

HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease.

Michelina Amato, Giuseppe Perrone, Daniela Righi, Claudio Pellegrini, Carla Rabitti, Francesco Di Matteo, Pierfilippo Crucitti, Damiano Caputo, Roberto Coppola, Giuseppe Tonini and 2 more

Open access · greenAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. HER2 discordance between primary and metastatic gastric cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Detection ofFrontiers in oncology · 2019
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Michelina AmatoDepartment of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy.
Giuseppe PerroneDepartment of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy. g.perrone@unicampus.it.
Daniela RighiDepartment of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy.
Claudio PellegriniDepartment of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy.
Carla RabittiDepartment of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy.
Francesco Di MatteoEndoscopic Unit, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy.
Pierfilippo CrucittiDepartment of Surgery, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy.
Damiano CaputoDepartment of Surgery, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy.
Roberto CoppolaDepartment of Surgery, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy.
Giuseppe ToniniOncology Unit, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy.
Daniele SantiniOncology Unit, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy.
Andrea Onetti MudaDepartment of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, Rome, Italy.
Università Campus Bio-Medico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HER2 (human epidermal growth factor receptor-2) assessment in histological samples of gastric cancer is essential to determine which patients might benefit from trastuzumab therapy. HER2 is often evaluated in primary tumor even if trastuzumab therapy is used to treat metastatic disease. However, the exact relationship in terms of HER2 status between primary and metastatic tumors has not been fully clarified. We aimed to evaluate the HER2 status concordance between primary gastric cancer and corresponding distant metastasis. HER2 status was evaluated by IHC (immunohistochemistry) and/or FISH ( fluorescence in situ hybridization) in 41 patients in primary gastric cancer and in paired metastasis. HER2 was assessed according scoring criteria applied in clinical approach. HER2 positivity was found in 14,6 % primary tumors and in 24,4%corresponding metastasis. HER2 concordance rate between primary and metastasis was 80,5 % (K-value = 0,388). Eight/41 (19,5 %)cases resulted discordant: 6 patients with metastatic HER2 positive lesions were found HER2 negative in primary cancers while 2 patient HER2 positive in primary lesion showed a negative conversion in metastasis. Our results showed a good concordance in terms of HER2 status between primary and metastatic lesions, as well as in biopsy and surgical removed specimens. However, the higher rate of HER2 positive status found in metastatic lesions underlined the importance of HER2 assessment in all samples obtained from different sites of gastric cancer disease.

Indexed as

Antineoplastic AgentsBiopsyErb-b2 Receptor Tyrosine KinasesFemaleHumansMaleMiddle AgedNeoplasm MetastasisStomach NeoplasmsTrastuzumabAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabFISHGastric cancerHER2ImmunoistochemistryMetastatic disease

Identifiers

PMID27363700
OpenAlexW2471512801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.